alexa T Cells as Treatment Targets in Systemic Lupus Erythema
ISSN: 2161-1149

Rheumatology: Current Research
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Review Article

T Cells as Treatment Targets in Systemic Lupus Erythematosus

Christine Konya and Vasileios C Kyttaris*

Beth Israel Deaconess Medical Center, Division of Rheumatology and Harvard Medical School, USA

*Corresponding Author:
Vasileios C Kyttaris
Division of Rheumatology and Harvard Medical School
330 Brookline Ave, CLS-936, Boston MA 02215, USA
Tel: 617-735-4162
Fax: 617-735-4170
E-mail: [email protected]

Received date: March 04, 2013; Accepted date: June 28, 2013; Published date: July 11, 2013

Citation: Konya C, Kyttaris VC (2013) T Cells as Treatment Targets in Systemic Lupus Erythematosus. Rheumatol Curr Res 3:120. doi: 10.4172/2161-1149.1000120

Copyright: © 2013 Konya C, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.



T cells play a central role in Systemic Lupus Erythematosus (SLE) pathogenesis. The discovery of key steps that lead to SLE T cell dysfunction allowed several investigators to propose targeted treatments for SLE. Herein, we discuss the potential of novel drugs targeting SLE T cells, such as fostamatinib and anti-IL-17 antibodies. Furthermore, we discuss the use of already approved medications such as rapamycin, dipyridamole and N acetylcysteine as targeted therapies for SLE.


Share This Page

Additional Info

Loading Please wait..
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version